Opioid Use Disorder Market Size, Share and Trends 2025 to 2034

Opioid Use Disorder Market Size and Forecast 2025 to 2034

The global opioid use disorder market size accounted for USD 5.31 billion in 2024 and is expected to exceed around USD 15.32 billion by 2034, growing at a CAGR of 11.18% from 2025 to 2034. The increasing rates of substance use disorders are the key factor driving the market growth. Also, rising government efforts to deal with these disorders, coupled with the increasing awareness of opioid use conditions, can fuel market growth shortly.

Opioid Use Disorder Market Key Takeaways

• North America dominated the global opioid use disorder market with the largest share of 69% in 2024.
• Asia Pacific is expected to grow at a double-digit CAGR of 12.5% over the studied period.
• By drug, the buprenorphine segment has held a major market share of 61% in 2024.
• By drug, the naltrexone segment is expected to grow at the fastest CAGR over the forecast period.
• By route of administration, the injectable administration segment accounted for the largest market share of 60% in 2024.
• By route of administration, the oral administration segment is anticipated to grow at the fastest rate over the forecast period.
• By distribution channel, the hospital pharmacies segment contributed the highest market share of 48% in 2024.

Role of Artificial Intelligence (AI) in Opioid Addiction Management

Artificial Intelligence models can help to detect the highest risk person for opioid addiction and can also implement insightful resources for the opioid use disorder market. This is useful for better management of pain among the population suffering from opioid addiction. Furthermore, GenAI can offer a more holistic approach to forecasting many outcomes based on patterns discovered from wide patient datasets.

• In February 2024, the U.S. General Services Administration (GSA) launched the Applied AI Healthcare Challenge, a prize competition seeking diverse and practical solutions to help federal agencies provide the highest level of medical care. GSA encourages large and small enterprises, women-owned, minority-owned, small disadvantaged, and service-disabled veteran-owned small businesses to participate. 

U.S. Opioid Use Disorder Market Size and Growth 2025 to 2034

The U.S. opioid use disorder market size was exhibited at USD 3.30 billion in 2024 and is projected to be worth around USD 9.64 billion by 2034, growing at a CAGR of 11.31% from 2025 to 2034.

North America dominated the global opioid use disorder market in 2024. The dominance of the region can be attributed to the increasing incidence of OUD, which fuels the substantial demand for new treatment options. The region also benefits from innovative healthcare infrastructure, development capabilities, and wide research. Furthermore, in North America, the U.S. led the market owing to the growing awareness among medical professionals regarding available treatments along with the surge in disease prevalence.

Asia Pacific is expected to show the fastest growth in the opioid use disorder market over the studied period. The growth of the segment can be credited to the increasing collaborations between local and international organizations. These partnerships are boosting innovation and other management strategies. In Asia Pacific, China dominated the market due to increasing government support for enhancing healthcare facilities and increasing adoption of opioids in pain management.

• In January 2023, Hikma Pharmaceuticals PLC revealed Naloxone Hydrochloride Injection, USP, 2mg/2mL, in the prefilled syringe (PFS) form. The drug is used to treat known or suspected opioid overdose. The launch expands the portfolio of addiction therapy treatments of the company.

Market Overview

Opioids are a set of painkillers that contain drugs that reduce pain, relax muscles, and relieve stress. Drugs such as oxycodone, codeine, hydrocodone, methadone, fentanyl, and other pharmaceutical medications are generally prescribed to treat severe or moderate pain. The excessive use of these drugs for pain treatment or any other purposes can lead to an illness called opioid usage disorder (OUD). Opioid drugs are mainly used to treat immediate pain after surgery. This factor can result in driving the opioid use disorder market.

Drug abuse statistics 2020

Opioid Use Disorder Market Growth Factors

• An increase in product launches and product approvals for these drugs is expected to boost opioid use disorder market growth soon.
• Growing consideration of buprenorphine patches for providing effective treatment solutions can propel market growth shortly.
• The surge in the adoption of key strategies including acquisition, collaboration, and agreement will likely contribute to the market expansion further.
• Rising utilization of e-prescriptions at hospitals coupled with other healthcare facilities and a surge in internet users.

Market Scope

Market Dynamics

Drivers

Rising admiration for buprenorphine patches 

Buprenorphine patches for tackling opioid addiction are increasingly becoming popular, as they are more effective in treating OUD. These patches have benefits such as decreased discomfort and enhanced drug delivery. They are the key choice for current opioid therapy, particularly for individuals who require continuous medications. In addition, the increasing prevalence of disease conditions like heart and cancer disease necessitates frequent use of opioids and other painkillers.

• In February 2024, Acadia Healthcare Company, Inc. announced the acquisition of three opioid treatment program clinics in South Carolina, which provide treatment for people seeking recovery from opioid use disorder. These facilities are the Company's first CTCs in South Carolina and offer care to all patients, including those covered by Medicaid.

Restraint

Side-effects from drug intake

The key factor that might hinder the opioid use disorder market growth is the side effects that can arise from the administration of drugs used for OUD treatment. The general side effects of these drugs are abdominal cramps, vomiting, diarrhea, respiratory complications, and constipation. Moreover, in severe cases of multiple side effects, the patient can also suffer from psychological disorders like anxiety and depression, hampering market growth further.

Opportunity

Rising R&D of novel drugs

The opioid use disorder market is witnessing substantial growth owing to the rising incidence of substance use conditions such as opioid addiction. Hence, the market players are working on developing innovative novel therapies to treat this addiction. These treatment solutions provide benefits over offering fast and strong rises in plasma levels, effectively inhibiting opioid receptors. Furthermore, digital therapeutics such as telecommuting and cognitive behavioral therapy are also gaining traction because of their effectiveness.

• In October 2023, -Netsmart announced the acquisition of Netalytics, a South Carolina-based addiction treatment software and practice management company, dedicated to developing technology for substance use disorder (SUD) providers focused on opioid addiction treatment. This acquisition will further extend the Netsmart CareFabric platform by enabling interoperable data sharing between opioid treatment program (OTP) facilities.

Drug Insights

The buprenorphine segment dominated the global opioid use disorder market in 2024. The dominance of the segment can be attributed to the effectiveness of this drug as a partial opioid agonist; this helps in increasing cravings and withdrawal symptoms while reducing euphoria and other associated risks. Additionally, the combination of naloxone and buprenorphine can deter opioid abuse further. The research also shows that raised buprenorphine doses can improve treatment results, especially in patients using fentanyl.

• In May 2023, the U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injection to treat moderate-to-severe opioid use disorder. The approval was based upon a randomized, double-blind, active-controlled clinical trial in 428 adults with a diagnosis of moderate-to-severe opioid use disorder.

The naltrexone segment is expected to grow at the fastest rate over the forecast period. The growth of the segment can be linked to its numerous benefits. As an opioid antagonist, it efficiently blocks opioid receptors, protecting from relapses by cutting the adverse effects of opioids. In addition, growing awareness and rising insurance coverage will likely fuel its adoption.

• In April 2024, California purchased CalRx Branded Over-the-Counter Naloxone for USD 24. Qualifying organizations in the state, including first responders, universities, and community organizations, can access the state's naloxone supply for free.

Route Of Administration Insights

The injectable administration segment led the global opioid use disorder market in 2024. The dominance of the segment can be credited to the advantages this route of administration provides. The injectable route can be used to deliver medications more rapidly and supplement calories. Furthermore, this route enables the drug to reach the bloodstream rapidly, which results in a quick onset of action. This is essential in controlling opioid withdrawal symptoms and also offers quick pain relief.

The oral administration segment is anticipated to grow at the fastest rate over the forecast period. The growth of the segment is due to the convenience it provides as it is non-invasive. Which in turn increases patient compliance and adherence. Medications like naltrexone and buprenorphine are much easier to manage and administer and require no specialized procedures or equipment. Also, oral medications can be administered at home easily.

Distribution Channel Insights

In 2024, the hospital pharmacies segment held the largest share of the opioid use disorder market. The dominance of the segment can be driven by the ability of hospital pharmacies to monitor and distribute specialized medications, like extended-release drugs and methadone. They also provide a controlled environment where drugs can be taken under stringent supervision, which is important for ensuring safety and adherence, especially for injectables.

Opioid Use Disorder Market Companies

• Teva Pharmaceutical Industries, Ltd.
• Pfizer, Inc.
• Collegium Pharmaceutical (BioDelivery Sciences International, Inc.)
• Alkermes, Inc.
• Orexo US, Inc. (a part of Orexo AB)
• Titan Pharmaceuticals, Inc.
• Omeros Corporation
• Camurus AB
• Hikma Pharmaceuticals PLC

Latest Announcement by Market Leaders

• In July 2024, Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. and Sanofi, announced an update to the timing for the anti-TL1A, duvakitug (formerly known as TEV-'574/SAR447189) program investigating the human IgG1-λ2 monoclonal antibody targeting TL1A for moderate-to-severe IBD. Teva and Sanofi are collaborating to co-develop and co-commercialize duvakitug for moderate-to-severe UC and CD patients.
• In January 2025, Hikma Pharmaceuticals announced an exclusive six-year commercial partnership with Emergent BioSolutions for the sale of KLOXXADO® (naloxone HCl nasal spray 8 mg) in the U.S. and Canada. KLOXXADO® received FDA approval in April 2021 for emergency treatment of suspected opioid overdose in adults and pediatric patients.

Recent Developments

• In July 2023, Titan Pharmaceuticals, Inc. entered into an Asset Purchase Agreement with Fedson, Inc. As part of this deal, Titan agreed to sell a portion of its ProNeura assets, including its portfolio of addiction treatment medications and other early-stage projects based on the ProNeura drug delivery technology. This portfolio included implant programs for Nalmefene and Probuphine.
• In May 2023, Indivior PLC received approval from the U.S. Food and Drug Administration for OPVEE (nalmefene) nasal spray for the treatment of opioid overdose induced by natural or synthetic opioids. OPVEE contains nalmefene, an opioid receptor that delivers fast onset and long-duration reversal of opioid-induced respiratory depression.

Segments Covered in the Report

By Drug  

• Naltrexone
• Buprenorphine
• BELBUCA
• Sublocade
• Suboxone
• Zubsolv
• Methadone
• Others

By Route Of Administration  

• Oral Administration
• Injectable Administration
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Others

By Geography

• North America
• Asia Pacific
• Europe
• Latin America
• Middle East and Africa